Supplementary Documents (Q2 YTD/FY2026)
Filed with TSE · · 22 pages · English
Watch Astellas Pharma's latest callAstellas Pharma (Tokyo:4503) Q4 2025 Earnings Call · Replay · Apr 27Read the transcript of Astellas Pharma (Tokyo:4503) Q4 2025 Earnings CallIn the deck
Earlier from Astellas Pharma
- Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
- Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
- Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Follow Astellas Pharma into a list and get an email when it puts out news.
Follow Astellas Pharma